Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

NCT07228390 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07228390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2025
Completion date
January 5, 2027
Enrollment
128 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa